BIPOLAR II DEPRESSION: LITHIUM, SSRI OR THE COMBINATION (NIH SPONSORED MULTI-CEN

双相 II 型抑郁症：锂、SSRI 或组合（NIH 赞助的多中心

• 批准号: 7951567
• 负责人: LORI L ALTSHULER
• 金额: $ 0.22万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951567
• 关键词: Adverse effects; Antidepressive Agents; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Lithium; Manic; Mood stabilizers; Outcome; Patients; Relative (related person); Research; Research Personnel; Resources; Selective Serotonin Reuptake Inhibitor; Sertraline; Source; United States National Institutes of Health; depression; hypomania; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Aims: 1. To determine the switch rate into hypomania or mania when treating patients with BD II depression with SSRI antidepressant (sertraline) monotherapy, mood stabilizer (lithium) monotherapy or the combination (lithium plus sertraline). 2. To assess the relative tolerability (side effects rate) of sertraline monotherapy vs. lithium monotherapy or the combination. 3. To determine good outcome rates defined as good antidepressant response without manic switch or unacceptable side effects.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 主要目的： 1。在治疗用SSRI抗抑郁药（舍曲林）单一疗法，情绪稳定剂（锂）单一疗法或组合（锂加锂加舍曲林）治疗BD II抑郁症患者时，要确定转向躁狂症或躁狂症。 2。评估舍曲林单一疗法与锂单一疗法或组合的相对耐受性（副作用率）。 3。确定良好的结果率定义为良好的抗抑郁反应，而无需躁狂转换或不可接受的副作用。